Xingming Zhang, Lou Geng, Li Yang, Yingying Wang, Zhihui Zou, Youping Zhang, Hanzhang Xu, Hu Lei, Yang Cao, Yingli Wu, Wenli Gu, Li Zhou
BACKGROUND: Despite some progress having been made regarding the treatment of T-cell acute lymphoblastic leukemia (T-ALL), the prognosis of T-ALL, particularly adult T-ALL, is still poor. Identifying novel, effective anti-T-ALL drugs is of great significance. Anlotinib, an oral tyrosine kinase inhibitor currently utilized in the treatment of lung cancer, exhibited a promising anti-T-ALL effect. A comprehensive study should therefore be conducted to explore both the in vitro as well as in vivo mechanisms of the anti-T-ALL effects of anlotinib...
August 4, 2023: Cellular Signalling